Morning Chippers,
Another question to put forth..
This issue may have been addressed, if so please disregard.
Concerning our American listed ADR's ( 40:1 ).
Code : BCHPY.
Has the EXTRA cost of purchasing this stock been resolved for American buyers, if not why not as this issue was raised some time ago. Naturally I have forgotten what this extra fee is called.
Non-existent trade in this is somewhat confusing as this was supposed to open us up to a far larger investing audience.
Like I said , this issue may have been resolved.
If one of our American share holders could comment on this issue will help decide if this issue should be put forth to Management , again.
Regards,
Esq.
The BCHPY ADR does not incur any extra fees as the shares are held by a bank here in the US. As the bank holds the stock, the purchaser does not own the underlying shares nor has the same rights as the original stockholder. I can purchase BCHPY from Fidelity here in the US without any extra fees, as they are built into the price of the ADR.
As I prefer to own the actual stock, I purchase BRCHF shares on the OTC markets instead. My only gripe is that each transaction, regardless of how many shares I purchased, is assessed a $50 foreign transaction fee through Fidelity.
Early in 2022, the company announced they were DTC eligible, but that was short-lived. This allowed me to purchase any amount of shares of BRCHF without requiring the foreign transaction fee. I inquired with Fidelity and BrainChip about this, and the last I knew, there was some problem with the paperwork they filed that required correction and resubmission.
My inquiry was about six months ago. This never made it to completion. I don't know why, and I gave up inquiring about it. I'm not sure whose responsibility was to get it done; maybe they had other priorities that came first. Either way, I go long periods between saving and buying shares because that $50 hit is a killer, especially when I could be buying a lot more shares for that money.